Screener
Immunome IMNM Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $5,534 | $3,339 |
| Accrued expenses and other current liabilities | 21,878 | 41,651 |
| Total current liabilities | 27,412 | 44,990 |
| Operating lease liabilities, net of current portion | 3,694 | 3,855 |
| Total liabilities | 31,106 | 48,845 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2026 and December 31, 2025 | — | — |
Item 1. Financial Statements.
FAQ
- What is Immunome's total current liabilities?
- Immunome (IMNM) reported total current liabilities of $27.41M in Q1 2026.
- How has Immunome's total current liabilities changed year-over-year?
- Immunome's total current liabilities decreased by 11.0% year-over-year, from $30.8M to $27.41M.
- What is the long-term trend for Immunome's total current liabilities?
- Over 5 years (2020 to 2025), Immunome's total current liabilities has grown at a 71.4% compound annual growth rate (CAGR), from $3.04M to $44.99M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Immunome's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude